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ABSTRACT 
Purpose: Cancer stem cells (CSCs) are thought to be responsible for tumor progression, 
metastasis, and recurrence.  HER2 overexpression is associated with increased CSCs, which may 
explain the aggressive phenotype and increased likelihood of recurrence for HER2+ breast 
cancers.  Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in 
normal tissues, providing potential for telomerase inhibition in anti-cancer therapy.  The purpose 
of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, 
imetelstat (GRN163L), on CSC and non-CSC populations of HER2+ breast cancer cell lines.   
Methods: The effects of imetelstat on CSC populations of HER2+ breast cancer cells were 
measured by ALDH activity and CD44/24 expression by flow cytometry as well as 
mammosphere assays for functionality.  Combination studies in vitro and in vivo were utilized to 
test for synergism between imetelstat and trastuzumab.  
Results: Imetelstat inhibited telomerase activity in both subpopulations.  Moreover, imetelstat 
alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC 
functional ability, as shown by decreased mammosphere counts and invasive potential.  Tumor 
growth rate was slower in combination treated mice compared to either drug alone.  
Additionally, there was a trend toward decreased CSC marker expression in imetelstat treated 
xenograft cells compared to vehicle control.  Furthermore, the observed decrease in CSC marker 
expression occurred prior to and after telomere shortening, suggesting imetelstat acts on the CSC 
subpopulation in telomere length independent and dependent mechanisms.   
Conclusions: Our study suggests addition of imetelstat to trastuzumab may enhance the effects of 
HER2 inhibition therapy, especially in the CSC population.    
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INTRODUCTION 
The cancer stem cell (CSC) hypothesis postulates that many cancers, including breast 
cancer, are hierarchically organized and a subpopulation of cells within the tumor possess the 
basic properties of stem cells, the ability to self-renew and differentiate  [1,2].  CSCs also have 
other stem cell-like properties including the active expression of telomerase, anti-apoptotic 
pathway activation, increased activity of membrane transporters, and an increased ability to 
migrate [3].  Evidence suggests that CSCs may be responsible for tumor progression, metastasis, 
chemotherapy and radiotherapy resistance, and subsequent tumor recurrence [4-8].  Breast CSCs 
can be identified using the cell surface marker expression CD44+/CD24- or elevated enzymatic 
activity of aldehyde dehydrogenase (ALDH) [1,9]. 
Multiple studies suggest Human Epidermal Growth Factor Receptor 2 (HER2) plays an 
important role in regulating the CSC population in HER2+ breast cancer.  HER2 overexpression 
and ALDH expression are significantly correlated in human breast cancer patient samples [9]. 
The CSC subpopulation in HER2 overexpressing breast cancer cell lines expresses the highest 
levels of HER2 protein without HER2 gene amplification changes [10].  Additionally, HER2 
overexpression expands the normal breast epithelial stem/early progenitor cell population, as 
well as the CSC population in malignant breast cells, resulting in increased tumorigenicity and 
invasiveness with HER2 amplification [11].  HER2 blockade via trastuzumab or HER2/EGFR 
blockade via lapatinib decreases the CSC population [10,11].  Neoadjuvant trastuzumab 
significantly increases pathologic complete response rate compared to chemotherapy alone, 
suggesting a reduction in the CSC population [12,13].  In contrast to chemotherapy, lapatinib 
reduced the CSC population in the neoadjuvant setting, although this decrease was not 
statistically significant [7]. 
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A hallmark of the cancer cell is its limitless replicative potential, achieved almost 
exclusively by telomere maintenance via telomerase reactivation [14].  Telomerase, the reverse 
transcriptase enzyme, is absent or lowly expressed in most normal somatic cells, but is highly 
expressed in cancer and enables malignant cells to maintain their telomere length just above the 
critically short threshold and thereby avoid senescence and apoptosis [15-18].  The differential 
expression between normal cells and cancer cells and the shorter telomere length of cancer cells 
makes telomerase inhibition a striking target for potential cancer therapeutics [19].  This 
potential led to the development of imetelstat (GRN163L), a lipidated 13-mer oligonucleotide 
N3′→P5′ thio phosphoramidate [20,21].  Imetelstat binds with high affinity to the template 
region of the RNA component of human telomerase resulting in competitive inhibition of 
telomerase enzymatic activity [22,23].  Our group and others have shown imetelstat alone, and in 
combination with chemotherapeutic agents or irradiation, can inhibit telomerase in a variety of 
tumor cells and compromise cancer cell viability and growth, both in vitro and in vivo [24-32].   
Telomerase is expressed in both bulk cancer cells and CSCs, suggesting CSCs could be 
sensitive to telomerase inhibition therapy [6,33].  Imetelstat has been shown to target the CSC 
population in a number of tumor types [34-37].  While these studies investigated changes in 
marker expression, spheroid formation, and tumor growth in vivo after imetelstat pretreatment, 
the effect of telomerase inhibition on invasion and metastases was not addressed nor the effect of 
imetelstat in combination with standard therapies on the CSC population.  Telomerase inhibitors 
are most effective when used in combination, likely due to the long lag time to achieve telomere 
shortening [38].  Our laboratory has shown imetelstat can augment the effects of trastuzumab 
and restore sensitivity in trastuzumab-resistant breast cancer cell lines [27]. 
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In this study, we investigated the effect of imetelstat and trastuzumab treatment in HER2+ 
breast cancer cell lines.  CSCs have active telomerase that can be inhibited by imetelstat 
treatment.  Imetelstat alone can decrease the percentage of CSCs, as well as inhibit 
mammosphere formation.  Additionally, we found imetelstat and trastuzumab combination 
treatment decreases the CSC population, mammosphere formation, invasive potential, and tumor 
growth in vivo.   
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MATERIALS AND METHODS 
Reagents 
The telomerase template antagonist, Imetelstat (GRN163L, 5ʹ-Palm-
TAGGGTTAGACAA-NH2-3ʹ), and its complimentary control oligonucleotide with the 
same chemistry (Sense, 5ʹ-Palm-ATCCAATCTGTT-NH2-3ʹ) were provided by Geron 
Corp and were prepared as previously described [23].  Trastuzumab was provided by the 
Indiana University Simon Cancer Center (IUSCC) Infusion Pharmacy.   
Cell Culture 
HCC1569 and HCC1954 breast cancer cell lines were purchased from ATCC (CRL-2330 
and CRL-2338) and cultured in RPMI media (Corning cellgro) containing 10% fetal 
bovine serum (FBS, Fisher Scientific).  SKBR3 and trastuzumab-resistant SKBR3-R pool 
1 cells were a gift from Dr. Francisco Esteva (MD Anderson Cancer Center) and were 
cultured in DMEM/F12 media containing 10% FBS.  Resistant cells (SKBR3-R) were 
cultured with the addition of 4 µg/mL trastuzumab [39].  TMD-231 cells were a gift from 
Dr. Harikrishna Nakshatri (Indiana University School of Medicine) [40] and were 
cultured in DMEM media containing 10% FBS.   
Treatment with Imetelstat and/or Trastuzumab 
Cells were allowed to attach overnight prior to drug treatment.  To refresh imetelstat, 
media was spiked with imetelstat every 3 days and all cells were counted and passaged 
every 6-7 days.  For the CSC marker expression studies, cells were treated with 2.5 µM 
imetelstat and/or trastuzumab [0.625 µM (1 trastuzumab: 4 imetelstat) for HCC1954 and 
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SKBR3 cells and 0.3125 µM (1 trastuzumab: 8 imetelstat) for HCC1569 cells]. For the 
cell sorting experiments, cells were treated with 2.5 µM imetelstat or sense 
oligonucleotide for 3 days for telomerase activity and 6 weeks for telomere length.   
Flow Cytometry and Fluorescence Activated Cell Sorting (FACS) 
Flow cytometric analysis was performed using an LSRII 407 nm laser cytometer (BD 
Biosciences) and cell sorting using a Special Order Research Product FACSAria sorter 
(BD Biosciences).  Cells were stained with APC-H7-conjugated CD44, PE-Cy7- 
conjugated CD24, and violet LIVE/DEAD fixable cell stain (all antibodies from BD 
Biosciences and viability stain from Life Technologies).  FMO (fluorescence minus one) 
controls were used to determine appropriate gates.  The Aldefluor assay was used to 
measure and separate cells based on ALDH activity according to manufacturer’s 
guidelines (StemCell Technologies).  Control samples treated with DEAB 
(diethylaminobenzaldehyde) were used for gating the negative population.  FlowJo 
software was used for all analyses. 
Methods for telomerase activity and telomere length determination, methylene blue cell 
proliferation for combination studies, mammosphere cultures, invasion assays, xenograft 
animal studies, and statistical analyses are available in supplemental information.   
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RESULTS 
Long term treatment with imetelstat inhibits cell growth 
 To study the effects of imetelstat treatment in HER2+ breast cancer cell lines, we first 
measured cumulative population doublings in two HER2+ cell lines not previously studied for 
telomerase inhibition, HCC1569 and HCC1954.  Cumulative population doublings of the 
HCC1569 and HCC1954 cell lines statistically significantly differed between imetelstat and 
untreated cells at the time point indicated by the arrow and remained different throughout the 
remainder of the experiment (Fig, S1, two-way repeated measures ANOVA, p < 0.05).   
HCC1569 cells stopped doubling and reached the stationary phase or plateau of the population 
doubling graph after 17 weeks of treatment.  HCC1954 reached the stationary phase after 10 
weeks of treatment.  The sense oligonucleotide control had a minor effect on cell proliferation, 
but it occurred much later than imetelstat and did not inhibit cells from continuing to proliferate.  
Although cumulative population doublings began to differ sooner in the HCC1569 cells, it took 
longer to reach the plateau than in HCC1954 cells.  The HCC1569 cells were slower growing, 
doubling about 4 times per week versus 5 times in the HCC1954, and have longer baseline 
telomere length, which may explain why a longer treatment regimen is required to reach the 
stationary phase in this cell line.  
HER2+ CSCs have active telomerase and are sensitive to telomerase inhibition via imetelstat 
 Previous studies have reported similar telomerase activity between CSCs and their bulk 
tumor cell counterparts, as well as similarities in telomere length [35,6].  We determined whether 
our HER2+ cell lines also had similar telomerase activity and telomere length in the CSC, non-
CSC (bulk tumor cells), and unsorted populations.  HCC1569 cell line was flow sorted based on 
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either CD44/CD24 expression or ALDH enzymatic activity.  Unsorted, non-CSC, and CSC 
populations all had active telomerase (Fig. 1a-b).  There was no difference in relative telomerase 
activity between CSC, non-CSC, and unsorted cells in the HCC1569 cell line based on 
CD44/CD24 expression (Fig. 1b, one-way ANOVA, p > 0.05 for untreated, sense, and imetelstat 
groups).  We also tested whether imetelstat can inhibit telomerase activity in the different 
subpopulations.  Imetelstat (163L) was able to abolish telomerase activity in both the CSC and 
non-CSC populations; however, as expected, the sense oligonucleotide control did not affect 
telomerase activity (Fig. 1a-b).  ALDH enzymatic activity was used to sort the HCC1954 cell 
line, as well as another HER2+ breast cancer cell line we have previously used for telomerase 
inhibition studies, the SKBR3 cell line [27].  Again, we found unsorted, non-CSC, and CSC 
populations had active telomerase that imetelstat was able to inhibit in both subpopulations (Fig. 
1c-d).  In line with the previous reports, we found similar average telomere length between the 
CSC and non-CSC populations in our HER2+ breast cancer cell lines (Fig. 1e, S2).  Six weeks of 
imetelstat treatment decreased average telomere length in the HCC1954 cell line, but not the 
HCC1569 cell line (Fig. 1e, S2).  HCC1569 cells had a longer baseline telomere length than 
HCC1954, possibly explaining why we did not see differences in average telomere length at this 
time point of treatment.  However, there appeared to be a shortening of longer telomeres in both 
cell lines with imetelstat treatment, shown by a shift downward in the telomere smear (Fig. 1e).  
Indeed, examination of the densitometry of the telomere smears revealed shortening of longer 
telomeres with imetelstat treatment, shown by a shift in the curve toward a smaller molecular 
weight (Fig. 1f). 
Telomerase inhibition can decrease CSCs and limit mammosphere formation 
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 The use of breast cancer cell lines to study CSCs has been validated [41,42].   SKBR3, 
HCC1954, and HCC1569 cell lines were subjected to flow cytometry analysis of CD44/CD24 
marker expression and ALDH enzymatic activity.  The HCC1569 cell line was positive for 
CD44 expression and contained positive and negative CD24 expressing cells, allowing us to use 
this cell line to measure the CD44+/CD24- CSC population (Fig. S3a).  Both HCC1954 and 
SKBR3 cell lines did not have a measureable CD44+/CD24- population (Fig. S3b-c).  As 
predicted by the correlation of HER2 and ALDH, all three cell lines had ALDH+ CSC 
subpopulations [9].   
 To determine the effect of telomerase inhibition on the CSC population, we measured 
CD44+/CD24- expression in the HCC1569 cell line.  Long-term treatment with imetelstat 
decreased the CSC population by more than twenty percent, whereas the sense oligonucleotide 
control had no effect on the CSC population (Fig. 2a-b).  Furthermore, imetelstat pretreatment 
significantly decreased mammosphere count, an in vitro assessment of stem cell function, 
compared to untreated and sense controls (Fig. 2c-e, one-way ANOVA, p < 0.05).   
Imetelstat augments the effects of trastuzumab in HER2+ breast cancer cell lines  
 Our lab has previously reported a synergistic effect of imetelstat and trastuzumab 
combination therapy in vitro [27].  We next verified this effect applied to the HCC1569 and 
HCC1954 cell lines, which have previously been classified as having a de novo resistance to 
trastuzumab [43].  IC50 values of trastuzumab and imetelstat were determined for both cell lines 
and used to select drug ratios for combination treatments. Trastuzumab and imetelstat 
combination shifted the dose-response curve and significantly decreased the concentration of 
both drugs needed to achieve the IC50 (Fig. 3).  Moreover, the combination index showed a 
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synergistic effect (CI < 1) at most concentrations tested (Table 1).  Although these cells are 
reported to be innately resistant to trastuzumab and we did notice little effect on cell proliferation 
at lower concentrations, we were able to determine IC50 values and showed combination 
treatment decreased the IC50 value for both trastuzumab and imetelstat.  These combination 
studies suggest imetelstat can augment the effects of trastuzumab.   
Imetelstat in combination with trastuzumab decreases the CSC population  
 We next wanted to determine the effect of imetelstat and trastuzumab combination 
treatment on the CSC population.  In accordance with Fig. 2, we found imetelstat alone was able 
to decrease the CSC population (Fig. 4a-c, green bars).  Although trastuzumab alone did not 
affect the percentage of CD44+/CD24- CSCs (Fig. 4a, red bars), we found trastuzumab decreased 
the ALDH+ CSC population (Fig. 4b-c, red bars) as previously published [10,11].  Combination 
treatment significantly decreased the CD44+/CD24- CSC population in the HCC1569 cell line (p 
< 0.05 for 12-54 days of treatment) (Fig. 4a, purple bars).  Moreover, combination treatment 
decreased the ALDH+ CSC population in all cell lines tested, although statistical analyses is 
hindered due to high variability of enzymatic activity (Fig. 4b-c, purple bars).  
We next wanted to determine if the decrease in the CSC population after combination 
treatment resulted in decreased functional ability of the CSCs.  We observed a significant 
decrease in mammosphere count and smaller spheroids following trastuzumab, imetelstat, and 
combination treatment after short term (12 days) and long term (90 days) pretreatment, 
suggesting CSC self-renewal is continually inhibited by these agents (Fig. 5a-b).  Moreover, 
short term treatment with imetelstat may not lead to telomere shortening, but long term treatment 
certainly does, suggesting imetelstat may inhibit the self-renewal potential of CSCs in telomere 
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length dependent and independent mechanisms. It has been reported that the CSC population has 
an increased invasive potential, an early step required for metastasis [44,41].  We performed 
invasion assays to determine if the decrease in CSCs following imetelstat and/or trastuzumab 
treatment correlated with decreased invasive potential.  Twelve day imetelstat and combination 
treatments significantly decreased the invasive potential compared to untreated samples, with 
less than half as many cells invading (Fig. 5c-d).   
Imetelstat and trastuzumab combination treatment decreases primary tumor growth in vivo 
 We and others have shown imetelstat treatment can decrease primary tumor growth in 
xenograft mouse models [24,28,30,31].  However, the effect of imetelstat and trastuzumab 
combination treatment on xenograft tumor growth has not previously been studied.  We found a 
significant decrease in primary tumor growth of HCC1954 cells implanted into the mammary fat 
pad of NSG mice and then treated with combination of imetelstat and trastuzumab (Fig. 6a).  
However, the study was concluded, due to burdensome tumor volume in the vehicle control 
group, before differences in tumor volume between the trastuzumab alone and combination 
group could be observed.   Tumor growth rates, calculated as the slope of the line of tumor 
volume versus days post inoculation, appeared to be different between combination and 
trastuzumab alone groups, suggesting addition of imetelstat can enhance the effects of 
trastuzumab on tumor growth (Fig. 6b).  HCC1954 cells did not reliably metastasize following 
tertiary passaging in mice (data not shown); therefore, we studied the effect of imetelstat alone in 
a triple negative breast cancer cell line, TMD-231 [45].  The primary tumor tissue from this 
study was digested to generate a single cell suspension, which were then grown in monolayer 
culture or subjected to flow cytometry analysis of CSC marker expression.  The PBS treated 
xenograft cells have a more mesenchymal-like phenotype with elongated morphology and 
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reduced cell-cell contact, a phenotype typical of breast CSCs [46], whereas the imetelstat treated 
xenograft cells have more epithelial morphologic features, namely rounder with more cell-cell 
contact (Fig. S4c).  Furthermore, there is a trend of decreased CSC marker expression in 
imetelstat treated xenograft cells compared to vehicle control, but this decrease was not 
statistically significant due to higher variability in the PBS group and small sample size (Fig. 
S4d).  These data suggest imetelstat can target the CSC population in vivo.   
 
 
15 
 
DISCUSSION 
Here, we show HER2+ CSCs have active telomerase that can be inhibited by imetelstat 
treatment, leading to telomere shortening.  Imetelstat treatment alone, and in combination with 
trastuzumab, decreased the number of CSCs, as well as their functional ability, as shown by 
decreased mammosphere count and invasive potential.  We report the first in vivo study of 
imetelstat and trastuzumab combination, in which the combination treatment has a slower tumor 
growth rate than either drug alone.  Additionally, we found a trend toward lower CSC marker 
expression in imetelstat treated xenograft cells compared to PBS control using a Triple Negative 
breast cancer cell line.  This study is the first to propose the decreased metastases and invasion 
following imetelstat treatment are due to decreased CSCs.  Moreover, we are the first to 
investigate the effect of imetelstat and trastuzumab combination therapy on the CSC population.  
 Interestingly, we observed a decrease in the CSC population following imetelstat 
treatment both prior to shortening of average telomere length and after telomere shortening, 
suggesting the effect of imetelstat on the CSC population may occur in telomere length 
dependent and independent mechanisms, as also reported in multiple myeloma [47].  This study 
suggested imetelstat can target the CSC population by impacting essential stem cell pathways 
during stem cell-fate decisions independent of telomere length and that imetelstat modulates 
CSC growth and self-renewal through decreasing telomere length [47].  In our study, the CSC 
and non-CSC populations have similar telomerase activity and average telomere length, 
discounting the possibility that CSCs have shorter baseline telomeres and thus require less time 
to reach critically short lengths.  While we did not observe shortening of average telomere length 
after 42 days of treatment in the HCC1569 cells (Fig. S2), imetelstat did shorten the longer 
telomeres at this time point (Fig. 1f).   Moreover, it has recently been published that 19 day 
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treatment of imetelstat affected telomere size distribution [32]; therefore, we cannot distinguish 
whether the decrease in CSCs, mammospheres, and invasive potential after 12 day treatment is 
due to telomere length dependent or independent mechanisms.   
A potential telomere length independent mechanism to explain the effect of imetelstat on 
CSCs could be due to reversal of the epithelial mesenchymal transition (EMT).  EMT activation 
is associated with maintenance of stem cell properties and acquisition of invasive and metastatic 
properties; EMT is able to generate CSCs [48,46,49].  We observed a change in cellular 
phenotype of imetelstat treated xenograft cells compared to PBS treated (Fig.  S4c).  EMT is 
crucial for the initial steps of metastasis; however, cells must then undergo a reversion of EMT 
termed MET to colonize a metastatic lesion [50].   Interestingly, a recent study investigated the 
off-target effects of imetelstat and found imetelstat disrupted the cytoskeleton through changes in 
actin, tubulin, and intermediate filament organization; furthermore, imetelstat decreased MMP2 
expression and subsequently invasive ability of lung cancer cells [51].  Of note, this study also 
found imetelstat treatment resulted in a loss of E-cadherin, which could suggest cells have 
undergone EMT, but are unable to subsequently undergo MET and cannot adhere to colonize a 
metastatic lesion.   
While EMT has been closely associated with CSCs, other studies suggest cells that 
undergo EMT are not the cells responsible for metastases [52].  Studies were carried out by Liu 
and collaborators to better understand the relationship between EMT, MET, and CSCs and 
furthermore distinguish between CD44+/CD24- CSCs and ALDH+ CSCs [53].  The researchers 
found many genes displayed reciprocal expression patterns between CD44+/CD24- and ALDH+ 
cell populations.  However, a set of transcripts expressed in CD44+/CD24- and ALDH+ cell 
populations overlapped with spheroid-forming cells, likely representing genes involved in stem 
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cell function.  These results suggest two stem cell compartments in human breast cancers are 
identified by CSC markers.  Moreover, CD44+/CD24- CSCs were significantly enriched in EMT- 
associated genes and ALDH+ CSCs were elevated in genes associated with the epithelial-like 
state [53].  Furthermore, purified CD44+/CD24- or ALDH+ cells were able to generate 
heterogeneous populations and recapitulate the populations present in the original cell line, 
suggesting CSCs display plasticity and are able to reversibly transition between the 
mesenchymal-like CD44+/CD24- CSC state and the epithelial-like ALDH+ CSC state [53].   This 
switching between two distinct EMT and non-EMT CSC populations is supported by work in 
squamous cell carcinoma in which CSCs behaved likewise [54].  Of note, it may be important to 
target both CSC populations as they can alternate between the two states [53].  Importantly, we 
show imetelstat alone and in combination with trastuzumab decreased CD44+/CD24- and ALDH+ 
CSCs in a number of cell lines and most notably both CSC populations in the HCC1569 cell line. 
In summary, our results show imetelstat treatment of HER2+ breast cancer cells leads to 
telomerase inhibition and decreases the CSC population alone and in combination with 
trastuzumab.  Markedly, imetelstat and trastuzumab combination is able to decrease the 
percentage of CD44+/CD24- and ALDH+ CSCs in the same cell line, suggesting this combination 
would be effective in targeting CSCs because cells would not benefit from transitioning to the 
other CSC state, which could potentially occur if we were only able to target one CSC state.  
Imetelstat decreased the self-renewal potential as well as invasive potential of the CSC 
population alone and in combination with trastuzumab.  CSCs are thought to be responsible for 
recurrent and metastatic disease and our study suggests adding imetelstat to trastuzumab 
treatment may provide a more durable clinical response for HER2+ breast cancer patients.   
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FIGURE LEGENDS 
Fig. 1 CSCs have active telomerase that can be inhibited by imetelstat leading to telomere 
shortening.  A) Detection of telomerase activity by TRAP assay of HCC1569 flow sorted CSCs 
and non-CSCs by marker expression following 3 day treatment.  UT= untreated cells, 163L= 
imetelstat treated cells B) Average quantification of relative telomerase activity from A) using 
ratio of telomerase products to internal standard, n = 3 for CD44/CD24 sorting and n = 2 for 
ALDH sorting, p = 0.2344 for UT, p = 0.4720 for sense, p = 0.5872 for 163L (one-way ANOVA 
comparing unsorted, CD44+/CD24-, and CD44+/CD24+) C) TRAP assay of SKBR3 and 
HCC1954 flow sorted CSCs and non-CSCs following 4 day treatment. D) Average 
quantification of relative telomerase activity from C), n = 2.  E) Telomere length determination 
by Terminal restriction fragment analysis of HCC1569 and HCC1954 flow sorted cells following 
6 weeks of treatment.  MWM= molecular weight marker, Unsort= unsorted cells, S= sense 
oligonucleotide control, HCC1569 CSC= CD44+/CD24-, HCC1569 non-CSC= CD44+/CD24+, 
HCC1954 CSC= ALDH+, HCC1954 non-CSC= ALDH- . F) Telomere length quantification 
using TELORUN of sorted HCC1569 (left panels) and HCC1954 (right panels) cells pretreated 
with imetelstat or untreated for 6 weeks prior to sorting CSC (top panels) and non-CSC (bottom 
panels) populations.  Shift in Molecular Weight (telomere length in Kb) after imetelstat treatment 
(red lines) shows telomere shortening of the longer telomeres within each sample.  a.u. = 
arbitrary units. 
Fig. 2 Imetelstat but not the sense oligonucleotide control decreases the CSC population and 
mammosphere counts. A) Scatter plot of CSC marker expression following treatment.  B) Flow 
cytometry analysis of CSC marker expression.  C) Representative images of mammosphere 
cultures following pretreatment.  D) Primary mammosphere count grouped by mammosphere 
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size (n=3), average ± SD, one-way ANOVA, * p<0.05, ** p< 0.01 compared to untreated.  E) 
Sum of mammosphere size groups as total mammosphere count, average ± SD, ANOVA, * p< 
0.05 compared to untreated. 
Fig. 3 Imetelstat augments the effects of trastuzumab in HER2+ breast cancer cells.  A) 
Representative dose-response curve for HCC1569 cells treated with imetelstat, trastuzumab, or 
1:8 combination for 5 days.  B) Average IC50 values of each drug as a single agent or in 
combination, Average + SD, n = 4, p = 0.0055 for imetelstat, p = 0.0470 for trastuzumab 
(Student’s t-test).  C) Representative dose-response curve for HCC1954 cells treated with 
imetelstat, trastuzumab, or 1:4 combination for 5 days. D) Average IC50 values of each drug as a 
single agent or in combination, Average + SD, n = 5, p = 0.0107 for imetelstat, p = 0.0058 for 
trastuzumab (Student’s t-test).  * = p < 0.05, ** = p < 0.01. 
Fig. 4 Imetelstat and trastuzumab combination treatment decreases CSCs.  A) CSC marker 
expression of HCC1569 cells analyzed by flow cytometry.  Average percent CD44+/CD24- + 
SD, n=3, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to untreated B) 
ALDH enzymatic activity of HCC1569 cells measured by flow cytometry.  Average percent 
ALDH+ + SD when error bars are shown, n=3, one-way ANOVA, * p < 0.05, ** p < 0.01 
compared to untreated C) ALDH enzymatic activity of HCC1954, SKBR3, and SKBR3-R cells 
measured by flow cytometry after 6 days of treatment.  Average percent ALDH+ + SD, n=3 
Fig. 5 Imetelstat and trastuzumab combination treatment inhibits mammosphere formation and 
invasive potential.  A) Total mammosphere counts from 12 and 90 day pretreatment HCC1569 
mammosphere cultures, Average ± SD, n=3, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 
0.001 compared to untreated.  B) Representative Images of Primary Mammospheres cultured 
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from HCC1569 cells, 4X Magnification, 200 µm scale bar.  C) Representative images of invaded 
cells in purple, 10X magnification, 60 µm scale bar.  D) Invaded cells in 10 random fields per 
well, Average ± SD, n=3, one-way ANOVA, ** p < 0.01 compared to untreated 
Fig. 6 Imetelstat, trastuzumab, and combination treatment decrease primary tumor growth in 
vivo.  A) Tumor volume of HCC1954 cells by caliper measurements in PBS control (thrice 
weekly, n=9), trastuzumab (20 mg/kg twice weekly, n=10), imetelstat (30 mg/kg, thrice weekly, 
n=10), and combination (trastuzumab twice weekly and imetelstat thrice weekly, n=9) treated 
NSG mice.  Average ± SEM B) Rate of tumor growth calculated from A) is the slope of line of 
the average tumor volume over time for each treatment group 
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Table 1 Combination Index Values for Trastuzumab and Imetelstat Combination Treatment 
                           
Cell Line 
[Imetelstat]      
(µM) 
[Trastuzumab] 
(µM) 
Combination  
Index 
HCC1569 0.156 
0.313 
0.625 
1.25 
2.5 
5 
10 
20 
40 
80 
0.020 
0.039 
0.078 
0.156 
0.313 
0.625 
1.25 
2.5 
5 
10 
0.466 
0.908 
0.554 
0.334 
0.295 
0.313 
1.148 
9.013 
0.327 
0.060 
HCC1954 0.156 
0.313 
0.625 
1.25 
2.5 
5 
10 
20 
40 
80 
0.039 
0.078 
0.156 
0.313 
0.625 
1.25 
2.5 
5 
10 
20 
0.137 
0.228 
0.322 
0.654 
1.136 
1.343 
1.301 
0.823 
0.723 
0.917 
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The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the 
cancer stem cell population and self-renewal of HER2+ breast cancer cells 
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SUPPORTING METHODS 
Telomerase Activity and Telomere Length Determination 
Telomerase activity was determined using the telomeric repeat amplification protocol 
(TRAP).  The TRAP assay was performed using the TRAPeze Telomerase Detection kit 
(Millipore) and a Cy5 fluorescently labelled TS primer according to established protocols 
[55,56].  Densitometry of the telomerase-specific ladder and internal standard was 
quantified using ImageJ and used to calculate Relative telomerase activity (RTA).  
Average telomere length was determined using the TeloTAGGG telomere length assay 
(Roche Diagnostics). The TeloTAGGG assay was preformed according to the 
manufacturer’s guidelines with these minor changes: 1) 1 µg genomic DNA was digested 
overnight; 2) the nylon membrane was hybridized with the telomere probe for 6 hours; 
and 3) the blot was exposed to X-ray film for 5-10 minutes.  Chemiluminescent detection 
of TRF’s was quantified using ImageQuant and average telomere length was calculated 
using TELORUN as previously described [57]. 
Methylene Blue Cell Proliferation Assay for Combination Studies 
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Cells were plated in 96 well microplates and treated for 5 days with a 1:2 serial dilution 
of imetelstat or trastuzumab.  To determine the effects of combination therapy, additional 
microplates were treated in parallel with 1:2 serial dilutions of imetelstat and 
trastuzumab, in which the two agents were at a 1:4 or 1:8 ratio (trastuzumab: imetelstat).   
Cell proliferation was determined via methylene blue staining as previously described 
[58] with minor changes.  Cells were fixed with 100% methanol for 15 minutes, stained 
with 0.05% methylene blue stain (Ricca Chemical) for 15 minutes, washed, dried, de-
stained with 0.5 M HCl, and analyzed using a plate reader at a 610 nm absorbance.  
Nonlinear regression sigmoidal curves were used to determine IC50 values.  Drug 
interactions were quantitated using the combination index from the Chou Talalay method 
[59] using CalcuSyn.   
Mammosphere and Invasion Assays 
15,000 cells were seeded into ultra-low attachment 6-well plates and cultured in 
MammoCult Medium (Stemcell Technologies).  After 7-10 days in culture, 
mammospheres were collected and quantified using a Z1 dual threshold Coulter Particle 
Counter (Beckman Coulter).  Invasive potential was determined using the Cell Invasion 
Assay (Millipore) per manufacturer’s instructions.  In brief, cells were pretreated to 
decrease CSC marker expression.  75,000 cells in serum-free media were seeded onto the 
top of the 24-well insert.  Media containing 10% FBS was placed in the bottom of the 
well.  Cells were allowed to invade for 72 hours at which point media and cells that had 
not invaded were removed by cotton swabs.  Bottom of the inserts were stained, rinsed, 
and analyzed under light microscope.  Ten random fields per well were counted. 
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Xenograft mice studies 
All animal experiments were approved and carried out in strict accordance by the 
Institutional Animal Care and Utilization Committee (Study number 3715 and 10711) at 
the Indiana University School of Medicine.  One million HCC 1954 (1:1 mix of serum 
free media and Matrigel) or TMD-231 (in serum free media) cells were implanted into 
the mammary fat pad of 5-7 week old female NSG mice.  Animals were treated with 
saline vehicle (thrice weekly), trastuzumab (20 mg/kg, twice weekly), and/or imetelstat 
(30 mg/kg, thrice weekly) by intraperitoneal injection.   Tumor volume was calculated as 
(length x width2) / 2 (in mm) by caliper measurements twice weekly.  After 7 weeks for 
TMD-231 and 10 weeks for HCC 1954, animals were euthanized and lungs and primary 
tumor were resected.  Lungs were formalin fixed, paraffin embedded, sectioned, and 
stained with hematoxylin and eosin (H&E) for analysis.  Primary tumor tissue was 
mechanically and enzymatically digested with collagenase/hyaluronidase solution, 
incubated for 2 hours, and passed through a 40 µm cell strainer to ensure single 
cellularity prior to cell culture or flow cytometry analysis. All procedures performed in 
studies involving animals were in accordance with the ethical standards of the institution 
or practice at which the studies were conducted. 
Statistical Analysis 
GraphPad Prism4 software was used to complete all statistical analyses.  Student’s t-test, 
one-way ANOVA with Tukey’s multiple comparisons post-tests, and two-way repeated 
measures ANOVA with Bonferroni post-tests were used to determine p-values.  In all 
experiments, p < 0.05 was considered statistically significant. 
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SUPPORTING FIGURE LEGENDS 
Fig. S1 Long-term treatment with imetelstat inhibits cellular proliferation.  Cumulative 
Population doublings graph of HCC1569 (A) and HCC1954 (B) cell lines. UT= untreated, 
163L= imetelstat 
Fig. S2 Average telomere length is similar in unsorted, CSC, and non-CSC populations.  
Average telomere length quantified from Fig. 1 E) using TeloRun.  Imetelstat is able to shorten 
average telomere length in HCC1954 cells, but not HCC1569 cells.  
Fig. S3 CSC marker expression of HER2+ breast cancer cell lines.  Flow cytometry analysis of 
CD44/CD24 (left panels) and ALDH enzymatic activity (right panels) of HCC1569 (A), 
HCC1954 (B), and SKBR3 (C) cell lines 
Fig. S4 Imetelstat decreases primary tumor growth, lung metastases, and CSCs.  A) Final tumor 
volume of TMD-231 tumors in PBS (n=7) and imetelstat (n=7) treated NSG mice.  B) H&E 
staining of lungs resected 7 weeks post inoculation following PBS or imetelstat treatment.  C)  
Resected primary tumors digested and cultured as xenograft cells.  Imetelstat treated cells appear 
more epithelial while PBS treated cells have a predominately mesenchymal phenotype, 10X 
magnification.  D) Flow cytometry analysis of CSC marker expression of primary tumors from 
A).  Average is lineated, p = 0.12  
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